SciELO - Scientific Electronic Library Online

vol.33 issue1Delayed onset of biologic or targeted synthetic dmards in rheumatoid arthritis patients and associated factorsSexual dysfunction in women with systemic sclerosis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista argentina de reumatología

Print version ISSN 0327-4411On-line version ISSN 2362-3675


QUINTANA, Rosana et al. Lupus in Argentina. . Rev. argent. reumatolg. [online]. 2022, vol.33, n.1, pp.14-25. ISSN 0327-4411.


lupus is a complex disease and often difficult to approach. Achieving remission is one of the objectives, incorporating therapeutic options.


to describe the characteristics of the patients and the use of belimumab, according to the status of the disease.

Materials and methods:

cross-sectional study. Patients of the RELESSAR registry. Stratification: Remission: SLEDAI=0 and without corticosteroids. Low disease activity SLEDAI> 0 and ≤4 and without corticosteroids and non-optimal control: SLEDAI> 4 and any dose of corticosteroids.


a total of 1,277 patients were included, 23.4% in remission, 12.6% in low disease activity and 63.8% in non-optimal control. The last group was younger and had a shorter duration of the disease. They had higher activity and chronicity indices and greater use of immunosuppressants. Only 22.3% of the patients with potential criteria for the use of belimumab (activity disease despite standard treatment) were receiving it. The variables associated with hospitalizations were: corticosteroids, cyclophosphamide and higher SLICC. Those associated with severe infection: mycophenolate mofetil, azathioprine, corticosteroids, and higher SLICC.


the complexity of the management of these patients is reflected, visualizing structural aspects such as inequality. The use of belimumab could be beneficial in selected patients.

Keywords : systemic lupus erythematosus; remission; low disease activity; belimumab; real-world data.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )